LFB USA, the Framingham, MA-based unit of France’s LFB Group, is building its first manufacturing facility in the U.S.
The biotech is investing $37 million to build a 65,000-square-foot manufacturing and laboratory facility in Marlborough, MA, according to the Milford Daily News. The company, which is getting incentives from the city, plans to add 50 jobs when the project is complete next year.
The plant will be used for early-stage processing of ATryn, a drug given to patients before surgery or childbirth who have a hereditary disease that can lead to blood clots. The drug will also be manufactured for rEVO Biologics, another unit of LFB, which is doing clinical trials on ATryn for treating the pregnancy complication preeclampsia.
“This is our signature capital investment,” William Gavin, LFB USA president said during a groundbreaking event, the newspaper reported. “We really need to scale this up for the market demand.”
- read the Daily News story
REVO looks to expand use of Atryn with preeclampsia PhIII